Analysts think OMER stock price could increase by 485%
Apr 05, 2025, 11:25 AM
1.42%
What does OMER do
Omeros, a Seattle-based biopharmaceutical company with 198 employees, focuses on developing therapeutics for immunologic disorders and is advancing several candidates, including narsoplimab and OMS527, in clinical trials. The company went public on October 8, 2009.
4 analysts think OMER stock price will increase by 485.13%. The current median analyst target is $41.31 compared to a current stock price of $7.06. The lowest analysts target is $36.36 and the highest analyst target is $47.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
